As the burgeoning marijuana market matures across North America, cannabinoid and its class of chemical compounds are turning into a treasure trove for pharmacological researchers. As the stigma behind cannabis fades, a new era of scientific breakthroughs stemmed from cannabinoids and their therapeutic possibilities is quickly developing. One company that is helping to lay the groundwork in bridging cannabinoids into being an accessible pharmaceutical option is Radient Technologies Inc. (RTI:CA).

In the past, extracting high-grade cannabinoids at a large-scale production level was not easy. Previous methods often produced inconsistent yield amounts combined with reduced purity levels, but Radient’s MAP™ extraction technology is erasing the past and pushing cannabinoids extraction well into the future.

Revolutionizing Cannabis Extraction with Aurora

The company’s proprietary technology was on full display in June of this year during testing for their joint venture with Aurora Cannabis (ACB:CA)(ACBFF), the largest licensed medical marijuana producer in Canada. These milestone results showed 98% extraction efficiency compared to conventional methods that usually range from 80-85%. Furthermore, the extraction technology demonstrated processing times of five minutes compared to approximately six hours for legacy methods. High purity levels were also observed for the extracts produced time and time again, at least equal with those attained using conventional methods. Joint data indicates that production levels in excess of 3,300 pounds per day can potentially be achieved using Radient’s proprietary large-scale continuous-flow MAP extractor.

“The positive outcome of the joint research project is a key milestone in the commercial development of Radient,” said Radient’s CEO, Denis Taschuk, after the results were announced. “With these results in our pocket, we are now able to commercialize our technology in what has become the fastest growing sector of the North American economy.”

Both sides deemed the test to be a great success and were excited by the possibilities of such a superior platform.

MAP™ Demonstration Facility

“Radient’s technology promises a significant advance in both quality and efficiency of cannabis extract production,” said Terry Booth, CEO of Aurora, at the time of the test results. This is especially important considering global market dynamics, which point to strong demand for cannabis derivative products. Importantly, Radient’s extraction technology has also been proven to deliver superior preservation of aromatic compounds known as terpenes, which are key to the cannabis consumer experience.”

Aurora clearly understands the importance of Radient’s technology and what it can mean in the growing trend of cannabinoid treatments.

“The ability to produce high-purity concentrates at very high throughputs, while preserving terpene profiles, will provide a substantial competitive advantage for us in addressing the high-growth concentrates market,” Booth added in press released at the time of the results.

Consequently, the company increased its stake in Radient by converting 14,285,714 shares at the end of July. However, this conversion was not a surprise. Aurora clearly understands the impact of Radient’s technology and what it can mean in a growing cannabis marketplace that is expected to see unparalleled growth in the near future. This conversion comes after Aurora previously invested $2 million in Radient and separately was the lead investor in a $6.0 million brokered private placement.

The work with Aurora is so important because more than 100 cannabinoids have been pinpointed, along with mounting confirmation as to the medical benefits to safely treat debilitating diseases and conditions like post-traumatic stress disorder, Multiple Sclerosis, chronic pain, gastro-intestinal maladies and much more, cannabinoid oil and extracts represent an exciting scientific space that can easily link to the pharmaceutical sector. Radient and Aurora’s partnership is a path toward large-scale, high-quality cannabinoid extraction that can easily access multiple strains based on Aurora’s rich supply. These facts make this a unique partnership in the cannabis space and have many excited about the future of the collaboration.

A Valuable Technology for Many Sectors

Besides breaking ground in the cannabis sector with Aurora, Radient’s MAP platform works with a range of biological materials and currently serves clients in the pharmaceutical, food and beverage, natural health, personal care and biofuel markets.

From their 20,000-square-foot GMP-approved facility in Edmonton, Radient’s MAP™ technology uses microwaves to cause an instant volumetric heating of the continuously-flowing material, enabling precise control of temperature and extraction time, both of which typically affect purity and extract profile. This careful control of extraction parameters is something that would be nearly impossible to achieve at large scale with different techniques. In addition, this volumetric heating ensures that any possible effects associated with excessive heating can be minimized and that all the material is extracted for the same time at the same temperature.

Thus, Radient’s superior technology makes sense with a diverse array of sectors. The company’s MAP technology can boost the commercial production of the booming cannabis sector, but also hypothetically improve a beverage company’s organic soda or improve cost-efficiency for a pharmaceutical company. Radient is not tied to one specific type of business because their technology platform is so versatile allowing them to carve out a market share in multiple industries.

72114582784157


In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.